TIOSPIRONE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H32N4O2S.ClH
Molecular Weight	477.062
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5

InChI

InChIKey=RYAWYTKDKQCORF-UHFFFAOYSA-N

InChI=1S/C24H32N4O2S.ClH/c29-21-17-24(9-3-4-10-24)18-22(30)28(21)12-6-5-11-26-13-15-27(16-14-26)23-19-7-1-2-8-20(19)31-25-23;/h1-2,7-8H,3-6,9-18H2;1H

HIDE SMILES / InChI

Molecular Formula	C24H32N4O2S
Molecular Weight	440.601
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800000562 | https://www.ncbi.nlm.nih.gov/pubmed/11007069 | https://www.ncbi.nlm.nih.gov/pubmed/2728088 | https://www.ncbi.nlm.nih.gov/pubmed/2885367 | https://www.ncbi.nlm.nih.gov/pubmed/2869146

Tiospirone (TSP) is an atypical antipsychotic drug. Tiaspirone appeared to be a promising antipsychotic agent as it didn`t cause extrapyramidal syndromes. It has 5HT-2 antagonistic properties as well as affinity for D2, 5HT-1a, 5HT-6 and sigma receptors. Tiospirone was in phase III clinical trials for the treatment of attention hyperactivity disorder with Mead Johnson in the USA but its development appears to have been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin 1a (5-HT1a) receptor 177 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11755134	Partial Agonist 297	4.65 nM [Ki]
Serotonin 2c (5-HT2c) receptor 131 Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10991983	Inverse Agonist 85	74.0 nM [IC50]
Serotonin 6 (5-HT6) receptor 44 Target ID: CHEMBL3371 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8522988	Antagonist 2849	950.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3294920 https://www.ncbi.nlm.nih.gov/pubmed/2885367	Primary		Phase III 665	Unknown Approved Use Unknown
Psychotic disorder 26 Sources: http://adisinsight.springer.com/drugs/800000562	Primary		Phase III 665	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYPs 33

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYPs 33	substrate 4014 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470571224.pse048	yes

Sourcing

Vendor/Aggregator	ID	URL
AOBIOUS INC	AOB5289	http://aobious.com/aobious/search?search_query=AOB5289
BOC Sciences	87691-91-6	http://www.bocsci.com/description.asp?cas=87691-91-6
Compound Cloud	55751
Compound Cloud	55752
eMolecules	110043328	https://orderbb.emolecules.com/search/#?query=110043328
eMolecules	300666089	https://orderbb.emolecules.com/search/#?query=300666089
eMolecules	43552516	https://orderbb.emolecules.com/search/#?query=43552516
Hangzhou Yuhao Chemical Technology	RT0936
MuseChem	R055594	https://www.musechem.com/product/R055594.html
Toronto Research Chemicals	T444810	https://www.trc-canada.com/product-detail/?CatNum=T444810

PubMed

Title	Date	PubMed
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.	2000-10	10991983
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.	1998-08-21	9760039
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.	1996-01	8522988
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.	1994-03	7908055

Patents

Sample Use Guides

In Vivo Use Guide

After a single 75 mg dose of tiospirone, demonstrable levels of dopamine binding activity were present. A variety of time points were sampled during the multiple dose study wherein subjects received 60 mg, t.i.d. for 28 days.

Route of Administration: Oral

In Vitro Use Guide

Tiaspirone was found to be a competitive, reversible inhibitor of the sodium-dependent high-affinity choline uptake (SDHACU) by crude hippocampal and striatal synaptosomal preparations, giving IC50 values of respectively 3.69 microM and 1.14 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:09 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:09 GMT 2025`
Record UNII	45Q1DF53NN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIOSPIRONE HYDROCHLORIDE

Official Name

English

BMY 13859-1

Preferred Name

English

TIOSPIRONE HYDROCHLORIDE [MART.]

Common Name

English

TIOSPIRONE HCL

Common Name

English

BMY-138591

Code

English

N-[4-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,1-cyclopentanediacetimide monohydrochloride

Systematic Name

English

BMY-13859-1

Code

English

TIOSPIRONE HYDROCHLORIDE [USAN]

Common Name

English

8-AZASPIRO(4.5)DECANE-7,9-DIONE, 8-(4-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)BUTYL)-, MONOHYDROCHLORIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28197